<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02906111</url>
  </required_header>
  <id_info>
    <org_study_id>MenSurgE2</org_study_id>
    <nct_id>NCT02906111</nct_id>
  </id_info>
  <brief_title>Vaginal Estriol Before and Vaginal Surgery for Prolapse</brief_title>
  <acronym>VSaE</acronym>
  <official_title>Effects on Vaginal Health and Quality of Life in Postmenopausal Women Using Ultra Low Topic Estriol Before Vaginal Surgery for Pelvic Statics Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Salvatore Caruso</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Policlinico Universitario, Catania</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the vaginal estriol before vaginal surgery
      for pelvic statics disorders is more efficacy of no estriol treatment on vaginal health and
      quality of life.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this randomized study was to evaluate the efficacy of low concentration of vaginal
      estriol gel (0.005%, 50 micrograms/1 g vaginal gel) in women with pelvic statics disorders
      before vaginal surgical treatment (group A), assessing the vaginal dryness, dysuria, vaginal
      maturation index (VMI), pH and the Vaginal Health Index (VHI). Secondary, to investigate the
      changes of sexual function and QoL. Women without pre surgical estriol treatment constituted
      the control group (group B).
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Vaginal Health Indexes</measure>
    <time_frame>vaginal gel containing 50 µg of estriol, daily, for a complete cycle of treatment of 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>QoL and sexual function were investigated by the Short Form 36 (SF-36)</measure>
    <time_frame>vaginal gel containing 50 µg of estriol, daily, for a complete cycle of treatment of 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire short form (PISQ-12), respectively</measure>
    <time_frame>vaginal gel containing 50 µg of estriol, daily, for a complete cycle of treatment of 12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">88</enrollment>
  <condition>Genital Prolapse</condition>
  <arm_group>
    <arm_group_label>Study Group on estriol vaginal gel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug: 1 g/daily of vaginal gel containing 50 μg of estriol (0.005%) for 3 weeks and then twice weekly for 9 weeks, for a complete cycle of treatment of 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group, no estriol treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Procedure: vaginal surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>estriol</intervention_name>
    <description>Study Group, treated with estriol
Control Group, no drug treatment
Both groups will undergo vaginal surgery for prolapse</description>
    <arm_group_label>Study Group on estriol vaginal gel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>vaginal surgery</intervention_name>
    <description>Control Group</description>
    <arm_group_label>Study Group on estriol vaginal gel</arm_group_label>
    <arm_group_label>Control group, no estriol treatment</arm_group_label>
    <other_name>vaginal surgery for prolapse</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  genital dryness,

          -  irritation/burning/itching of vulvas or vagina

          -  decreased lubrication with sexual activity

          -  discomfort or pain with sexual activity

          -  decreased arousal, orgasm, desire

          -  dysuria.

        Exclusion Criteria:

          -  previous surgeries for pelvic organ prolapse

          -  urinary incontinence

          -  usage of medication

          -  chronic medical illness

          -  body mass index (BMI) ≥ 35 kg/m2

          -  endometrial thickness equal to or greater than 4 mm

          -  abnormal uterine bleeding

          -  hormone-dependent malignancies

          -  history of thromboembolic disease

          -  liver disease

          -  usage of HT for less than 3 months

          -  usage of phytoestrogens within 1 month before the start of the study

          -  partner affected by sexual disorder

          -  conflicting with the partner
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>56 Years</minimum_age>
    <maximum_age>63 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio Cianci, Prof</last_name>
    <role>Study Chair</role>
    <affiliation>Policlinico Catania</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Salvatore Caruso, Prof</last_name>
    <phone>+390953781101</phone>
    <email>scaruso@unict.it</email>
  </overall_contact>
  <results_reference>
    <citation>Caruso S, Cianci S, Amore FF, Ventura B, Bambili E, Spadola S, Cianci A. Quality of life and sexual function of naturally postmenopausal women on an ultralow-concentration estriol vaginal gel. Menopause. 2016 Jan;23(1):47-54. doi: 10.1097/GME.0000000000000485.</citation>
    <PMID>26079974</PMID>
  </results_reference>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 24, 2016</study_first_submitted>
  <study_first_submitted_qc>September 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2016</study_first_posted>
  <last_update_submitted>September 14, 2016</last_update_submitted>
  <last_update_submitted_qc>September 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Policlinico Universitario, Catania</investigator_affiliation>
    <investigator_full_name>Salvatore Caruso</investigator_full_name>
    <investigator_title>Professor of Gynecology, Clinic of Gynecology</investigator_title>
  </responsible_party>
  <keyword>Estriol</keyword>
  <keyword>Prolapse</keyword>
  <keyword>Quality of life</keyword>
  <keyword>Vaginal health</keyword>
  <keyword>Vaginal surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prolapse</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

